Kosj Yamoah1, Timothy N Showalter2, Nitin Ohri3. 1. Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. 2. Department of Radiation Oncology, University of Virginia School of Medicine, Charlottesville, Virginia. 3. Department of Radiation Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York. Electronic address: ohri.nitin@gmail.com.
Abstract
PURPOSE: To systematically review the outcomes of randomized trials testing radiation therapy (RT) intensification, including both dose escalation and/or the use of altered fractionation, as a strategy to improve disease control for a number of malignancies. METHODS AND MATERIALS: We performed a literature search to identify randomized trials testing RT intensification for cancers of the central nervous system, head and neck, breast, lung, esophagus, rectum, and prostate. Findings were described qualitatively. Where adequate data were available, pooled estimates for the effect of RT intensification on local control (LC) or overall survival (OS) were obtained using the inverse variance method. RESULTS: In primary central nervous system tumors, esophageal cancer, and rectal cancer, randomized trials have not demonstrated that RT intensification improves clinical outcomes. In breast cancer and prostate cancer, dose escalation has been shown to improve LC or biochemical disease control but not OS. Radiation therapy intensification may improve LC and OS in head and neck and lung cancers, but these benefits have generally been limited to studies that did not incorporate concurrent chemotherapy. CONCLUSIONS: In randomized trials, the benefits of RT intensification have largely been restricted to trials in which concurrent chemotherapy was not used. Novel strategies to optimize the incorporation of RT in the multimodality treatment of solid tumors should be explored.
PURPOSE: To systematically review the outcomes of randomized trials testing radiation therapy (RT) intensification, including both dose escalation and/or the use of altered fractionation, as a strategy to improve disease control for a number of malignancies. METHODS AND MATERIALS: We performed a literature search to identify randomized trials testing RT intensification for cancers of the central nervous system, head and neck, breast, lung, esophagus, rectum, and prostate. Findings were described qualitatively. Where adequate data were available, pooled estimates for the effect of RT intensification on local control (LC) or overall survival (OS) were obtained using the inverse variance method. RESULTS: In primary central nervous system tumors, esophageal cancer, and rectal cancer, randomized trials have not demonstrated that RT intensification improves clinical outcomes. In breast cancer and prostate cancer, dose escalation has been shown to improve LC or biochemical disease control but not OS. Radiation therapy intensification may improve LC and OS in head and neck and lung cancers, but these benefits have generally been limited to studies that did not incorporate concurrent chemotherapy. CONCLUSIONS: In randomized trials, the benefits of RT intensification have largely been restricted to trials in which concurrent chemotherapy was not used. Novel strategies to optimize the incorporation of RT in the multimodality treatment of solid tumors should be explored.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Nitin Ohri; Xinglei Shen; Adam P Dicker; Laura A Doyle; Amy S Harrison; Timothy N Showalter Journal: J Natl Cancer Inst Date: 2013-03-06 Impact factor: 13.506
Authors: Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta Journal: N Engl J Med Date: 2014-02-20 Impact factor: 91.245
Authors: Alan Pollack; Gail Walker; Eric M Horwitz; Robert Price; Steven Feigenberg; Andre A Konski; Radka Stoyanova; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; Charlie Ma; Mark K Buyyounouski Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: H K Awwad; M Lotayef; T Shouman; A C Begg; G Wilson; S M Bentzen; H Abd El-Moneim; S Eissa Journal: Br J Cancer Date: 2002-02-12 Impact factor: 7.640
Authors: David P Dearnaley; Gordana Jovic; Isabel Syndikus; Vincent Khoo; Richard A Cowan; John D Graham; Edwin G Aird; David Bottomley; Robert A Huddart; Chakiath C Jose; John H L Matthews; Jeremy L Millar; Claire Murphy; J Martin Russell; Christopher D Scrase; Mahesh K B Parmar; Matthew R Sydes Journal: Lancet Oncol Date: 2014-02-26 Impact factor: 41.316
Authors: Jing Zhao; Regina M Day; Jian-Yue Jin; Leslie Quint; Hadyn Williams; Catherine Ferguson; Li Yan; Maurice King; Ahmad Albsheer; Martha Matuszak; Feng-Ming Spring Kong Journal: Oncotarget Date: 2017-06-29
Authors: Johanna Ramroth; David J Cutter; Sarah C Darby; Geoff S Higgins; Paul McGale; Mike Partridge; Carolyn W Taylor Journal: Int J Radiat Oncol Biol Phys Date: 2016-07-25 Impact factor: 7.038
Authors: David B Landau; Laura Hughes; Angela Baker; Andrew T Bates; Michael C Bayne; Nicholas Counsell; Angel Garcia-Alonso; Susan V Harden; Jonathan D Hicks; Simon R Hughes; Marianne C Illsley; Iftekhar Khan; Virginia Laurence; Zafar Malik; Helen Mayles; William Philip M Mayles; Elizabeth Miles; Nazia Mohammed; Yenting Ngai; Emma Parsons; James Spicer; Paula Wells; Dean Wilkinson; John D Fenwick Journal: Int J Radiat Oncol Biol Phys Date: 2016-03-28 Impact factor: 7.038